Literature DB >> 9658124

Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus.

P Gallinari1, D Brennan, C Nardi, M Brunetti, L Tomei, C Steinkühler, R De Francesco.   

Abstract

The hepatitis C virus (HCV) nonstructural 3 protein (NS3) contains at least two domains associated with multiple enzymatic activities; a serine protease activity resides in the N-terminal one-third of the protein, whereas RNA helicase activity and RNA-stimulated nucleoside triphosphatase activity are associated with the C-terminal portion. To study the possible mutual influence of these enzymatic activities, a full-length NS3 polypeptide of 67 kDa was expressed as a nonfusion protein in Escherichia coli, purified to homogeneity, and shown to retain all three enzymatic activities. The protease activity of the full-length NS3 was strongly dependent on the activation by a synthetic peptide spanning the central hydrophobic core of the NS4A cofactor. Once complexed with the NS4A-derived peptide, the full-length NS3 protein and the isolated N-terminal protease domain cleaved synthetic peptide substrates with comparable efficiency. We show that, as in the case of the isolated protease domain, the protease activity of full-length NS3 undergoes inhibition by the N-terminal cleavage products of substrate peptides corresponding to the NS4A-NS4B and NS5A-NS5B. We have also characterized and quantified the NS3 ATPase, RNA helicase, and RNA-binding activities under optimized reaction conditions. Compared with the isolated N-terminal and C-terminal domains, recombinant full-length NS3 did not show significant differences in the three enzymatic activities analyzed in independent in vitro assays. We have further explored the possible interdependence of the NS3 N-terminal and C-terminal domains by analyzing the effect of polynucleotides on the modulation of all NS3 enzymatic functions. Our results demonstrated that the observed inhibition of the NS3 proteolytic activity by single-stranded RNA is mediated by direct interaction with the protease domain rather than with the helicase RNA-binding domain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658124      PMCID: PMC109884     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Use of T7 RNA polymerase to direct expression of cloned genes.

Authors:  F W Studier; A H Rosenberg; J J Dunn; J W Dubendorff
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

2.  Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity.

Authors:  N J Butkiewicz; M Wendel; R Zhang; R Jubin; J Pichardo; E B Smith; A M Hart; R Ingram; J Durkin; P W Mui; M G Murray; L Ramanathan; B Dasmahapatra
Journal:  Virology       Date:  1996-11-15       Impact factor: 3.616

3.  A zinc binding site in viral serine proteinases.

Authors:  R De Francesco; A Urbani; M C Nardi; L Tomei; C Steinkühler; A Tramontano
Journal:  Biochemistry       Date:  1996-10-15       Impact factor: 3.162

4.  Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.

Authors:  J L Kim; K A Morgenstern; C Lin; T Fox; M D Dwyer; J A Landro; S P Chambers; W Markland; C A Lepre; E T O'Malley; S L Harbeson; C M Rice; M A Murcko; P R Caron; J A Thomson
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

5.  Complex formation between the hepatitis C virus serine protease and a synthetic NS4A cofactor peptide.

Authors:  E Bianchi; A Urbani; G Biasiol; M Brunetti; A Pessi; R De Francesco; C Steinkühler
Journal:  Biochemistry       Date:  1997-06-24       Impact factor: 3.162

6.  Structure of the hepatitis C virus RNA helicase domain.

Authors:  N Yao; T Hesson; M Cable; Z Hong; A D Kwong; H V Le; P C Weber
Journal:  Nat Struct Biol       Date:  1997-06

7.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

8.  The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.

Authors:  R A Love; H E Parge; J A Wickersham; Z Hostomsky; N Habuka; E W Moomaw; T Adachi; Z Hostomska
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

9.  Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of a hepatitis C virus NS3-NS4A complex isolated from transfected COS cells.

Authors:  K A Morgenstern; J A Landro; K Hsiao; C Lin; Y Gu; M S Su; J A Thomson
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

10.  A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain.

Authors:  F Preugschat; D R Averett; B E Clarke; D J Porter
Journal:  J Biol Chem       Date:  1996-10-04       Impact factor: 5.157

View more
  48 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  ATP binding and ATPase activities associated with recombinant rabbit hemorrhagic disease virus 2C-like polypeptide.

Authors:  M S Marín; R Casais; J M Alonso; F Parra
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335.

Authors:  Christopher T Lemke; Nathalie Goudreau; Songping Zhao; Oliver Hucke; Diane Thibeault; Montse Llinàs-Brunet; Peter W White
Journal:  J Biol Chem       Date:  2011-01-26       Impact factor: 5.157

4.  The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently.

Authors:  David N Frick; Ryan S Rypma; Angela M I Lam; Baohua Gu
Journal:  J Biol Chem       Date:  2003-10-29       Impact factor: 5.157

5.  Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.

Authors:  Keith P Romano; Akbar Ali; William E Royer; Celia A Schiffer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-17       Impact factor: 11.205

6.  Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease.

Authors:  Keith P Romano; Jennifer M Laine; Laura M Deveau; Hong Cao; Francesca Massi; Celia A Schiffer
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

7.  Purification and characterization of West Nile virus nucleoside triphosphatase (NTPase)/helicase: evidence for dissociation of the NTPase and helicase activities of the enzyme.

Authors:  P Borowski; A Niebuhr; O Mueller; M Bretner; K Felczak; T Kulikowski; H Schmitz
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

8.  Dual inhibition of HCV and HIV by ring-expanded nucleosides containing the 5:7-fused imidazo[4,5-e][1,3]diazepine ring system. In vitro results and implications.

Authors:  Ning Zhang; Peng Zhang; Andrea Baier; Lucyna Cova; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2014-01-08       Impact factor: 2.823

9.  Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.

Authors:  Partha K Chandra; Sidhartha Hazari; Bret Poat; Feyza Gunduz; Ramesh Prabhu; Gerald Liu; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

10.  UK-1 and structural analogs are potent inhibitors of hepatitis C virus replication.

Authors:  Dawn N Ward; Daniel C Talley; Mrinalini Tavag; Samrawit Menji; Paul Schaughency; Andrea Baier; Paul J Smith
Journal:  Bioorg Med Chem Lett       Date:  2013-12-09       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.